Prestige Consumer Healthcare (NYSE:PBH) VP Jeffrey Zerillo Sells 1,207 Shares
by Teresa Graham · The Cerbat GemPrestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Jeffrey Zerillo also recently made the following trade(s):
- On Tuesday, May 5th, Jeffrey Zerillo sold 346 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $55.32, for a total transaction of $19,140.72.
- On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $65.93, for a total value of $65,930.00.
Prestige Consumer Healthcare Stock Performance
Shares of NYSE:PBH traded up $0.18 during midday trading on Thursday, hitting $54.49. The company’s stock had a trading volume of 577,038 shares, compared to its average volume of 462,042. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of 14.42, a PEG ratio of 1.67 and a beta of 0.40. The stock’s 50 day simple moving average is $60.52 and its 200 day simple moving average is $61.97. Prestige Consumer Healthcare Inc. has a fifty-two week low of $51.24 and a fifty-two week high of $89.37. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same period last year, the business earned $1.22 earnings per share. The firm’s quarterly revenue was down 2.4% compared to the same quarter last year. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.54 earnings per share for the current year.
Analyst Ratings Changes
PBH has been the subject of a number of analyst reports. Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Finally, Oppenheimer cut their target price on shares of Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $74.75.
Institutional Trading of Prestige Consumer Healthcare
Institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $36,954,000. Nordea Investment Management AB boosted its holdings in shares of Prestige Consumer Healthcare by 547.4% in the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after buying an additional 520,186 shares during the last quarter. Brandes Investment Partners LP lifted its stake in Prestige Consumer Healthcare by 93.2% in the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after acquiring an additional 292,744 shares during the last quarter. Capital Research Global Investors lifted its stake in Prestige Consumer Healthcare by 107.9% in the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock valued at $34,639,000 after acquiring an additional 291,425 shares during the last quarter. Finally, Tributary Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 157.3% in the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after acquiring an additional 231,969 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).